198 related articles for article (PubMed ID: 37359513)
1. Single-cell sequencing in primary intraocular tumors: understanding heterogeneity, the microenvironment, and drug resistance.
He LF; Mou P; Yang CH; Huang C; Shen Y; Zhang JD; Wei RL
Front Immunol; 2023; 14():1194590. PubMed ID: 37359513
[TBL] [Abstract][Full Text] [Related]
2. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
3. Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology.
Sun S; Shi R; Xu L; Sun F
Melanoma Res; 2022 Feb; 32(1):18-26. PubMed ID: 34879031
[TBL] [Abstract][Full Text] [Related]
4. Integration of Bulk RNA Sequencing and Single-Cell RNA Sequencing to Reveal Uveal Melanoma Tumor Heterogeneity and Cells Related to Survival.
Gao G; Deng A; Liang S; Liu S; Fu X; Zhao X; Yu Z
Front Immunol; 2022; 13():898925. PubMed ID: 35865532
[TBL] [Abstract][Full Text] [Related]
5. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis reveals the dysfunction of signaling pathways in uveal melanoma.
Sun S; Guo B; Xu L; Shi R
BMC Cancer; 2022 Jul; 22(1):734. PubMed ID: 35790930
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.
Hu Y; Cai J; Ye M; Mou Q; Zhao B; Sun Q; Lou X; Zhang H; Zhao Y
Front Immunol; 2022; 13():1037128. PubMed ID: 36466923
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.
de Lange MJ; van Pelt SI; Versluis M; Jordanova ES; Kroes WG; Ruivenkamp C; van der Burg SH; Luyten GP; van Hall T; Jager MJ; van der Velden PA
Oncotarget; 2015 Nov; 6(35):37824-35. PubMed ID: 26462151
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic genes in uveal melanoma microenvironment.
Luo H; Ma C
PLoS One; 2020; 15(11):e0242263. PubMed ID: 33196683
[TBL] [Abstract][Full Text] [Related]
10. Uveal melanoma: A pathologist's perspective and review of translational developments.
Schoenfield L
Adv Anat Pathol; 2014 Mar; 21(2):138-43. PubMed ID: 24508696
[TBL] [Abstract][Full Text] [Related]
11. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
12. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
13. The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors.
Bornfeld N; Biewald E; Bauer S; Temming P; Lohmann D; Zeschnigk M
Dtsch Arztebl Int; 2018 Feb; 115(7):106-111. PubMed ID: 29510820
[TBL] [Abstract][Full Text] [Related]
14.
Meng Z; Chen Y; Wu W; Yan B; Zhang L; Chen H; Meng Y; Liang Y; Yao X; Luo J
Front Immunol; 2022; 13():754645. PubMed ID: 35281030
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Zhang J; Liu S; Ye Q; Pan J
Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394
[TBL] [Abstract][Full Text] [Related]
16. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic insights into uveal melanoma.
Sharma A; Stei MM; Fröhlich H; Holz FG; Loeffler KU; Herwig-Carl MC
Clin Genet; 2018 May; 93(5):952-961. PubMed ID: 28902406
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
19. Targeting tyrosine kinases for treatment of ocular tumors.
Jo DH; Kim JH; Kim JH
Arch Pharm Res; 2019 Apr; 42(4):305-318. PubMed ID: 30470974
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.
Harda K; Szabo Z; Szabo E; Olah G; Fodor K; Szasz C; Mehes G; Schally AV; Halmos G
Molecules; 2018 Jun; 23(7):. PubMed ID: 29949880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
